Bourne CM, Wallisch P, Dacek MM, Gardner TJ, Pierre S, Vogt K, Corless BC, Bah MA, Romero-Pichardo JE, Charles A et al..  2023.  Host Interactions with Engineered T-cell Micropharmacies.. Cancer Immunol Res. 11(9):1253-1265.

Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S, Olsen KMoore, Gregg A, Noggle S, Tessier-Lavigne M.  2016.  Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.. Nature. 533(7601):125-9.

González F, Zhu Z, Shi Z-D, Lelli K, Verma N, Li QV, Huangfu D.  2014.  An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells.. Cell Stem Cell. 15(2):215-226.

Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A et al..  2011.  Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.. Proc Natl Acad Sci U S A. 108(51):E1408-16.